Blueprint Medicines Corporation Stock News

Blueprint Medicines Corp:

Blueprint Medicines (NASDAQ:BPMC) announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors.In patients with RET-

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key miles

S&P Biotech ETF (XBI) slumped -20% year-to-date, in-line with the S&P 500, due to the unrelenting coronavirus pandemic,. Heavy exposure to small caps contribute

Laekna Therapeutics Shanghai acquired global rights to Novartis' anti-PD-L1 antibody. Tyligand Bioscience acquired exclusive China rights to onapristone ER from

Wall Street brokerages expect that Blueprint Medicines Corp (NASDAQ:BPMC) will report sales of $4.83 million for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have

Blueprint Medicines Corp (NASDAQ:BPMC) insider Marion Dorsch sold 1,214 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $52.49, for a

Alliancebernstein L.P. lifted its holdings in shares of Blueprint Medicines Corp (NASDAQ:BPMC) by 5.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commissi

Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $52.10, for a total tr

Blueprint Medicines Corp (NASDAQ:BPMC) shares traded down 5.1% during mid-day trading on Friday following insider selling activity. The company traded as low as $56.95 and last traded at $58.11, 843,3

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

Great West Life Assurance Co. Can boosted its position in Blueprint Medicines Corp (NASDAQ:BPMC) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exch

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avaprit